We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Optibrium and NextMove Software Announce Technology Collaboration

Optibrium and NextMove Software Announce Technology Collaboration

Optibrium and NextMove Software Announce Technology Collaboration

Optibrium and NextMove Software Announce Technology Collaboration

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Optibrium and NextMove Software Announce Technology Collaboration"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Optibrium™ and NextMove Software have announced an agreement to collaborate on the integration of NextMove Software’s Matsy technology with Optibrium’s StarDrop software suite. The combination of these technologies will help guide scientists to quickly identify novel compounds based on matched molecular series analysis with a high chance of success for their drug discovery projects.

The Matsy algorithm has been developed by NextMove Software to generate and search databases of matched molecular series to identify chemical substitutions that are most likely to improve target activity (J. Med. Chem., 2014, 57(6), pp 2704-2713). This goes beyond conventional ‘matched molecular pair analysis’ by using data from longer series of matched compounds (and not just pairs) to make more relevant predictions for a particular chemical series of interest.

As part of the collaboration with Optibrium, Matsy will be applied in StarDrop’s Nova™ module, which automatically generates new compound structures to stimulate the search for optimization strategies related to initial hit or lead compounds. StarDrop’s unique capabilities for multi-parameter optimization and predictive modelling will enable efficient prioritization of the resulting ideas to identify high quality compounds with the best chance of success.

Dr Matthew Segall, Optibrium’s CEO, commented: “We are delighted to announce our collaboration with NextMove Software, which has a proven track record of developing innovative informatics solutions for pharma companies world-wide. We remain committed to working with NextMove and our other partners to provide access to the leading compound optimization technologies through StarDrop’s unique environment that guides efficient discovery of novel, high quality drugs.”

Dr Roger Sayle, CEO of NextMove Software added “We are excited to be working together with Optibrium to combine the Matsy technology with StarDrop’s intuitive interface for compound generation.”

The results of this collaboration will be available in a future version of StarDrop, expected to be released during 2015.